Published by Frank Prenesti on 24th June 2021
(Sharecast News) - AstraZeneca and MSD's Lynparza prostate cancer drug has been granted conditional approval in China after a successful phase three trial, the companies said on Thursday.
URL: http://www.digitallook.com/dl/news/story/31941059/...